Short Term Genetic Effects of Chemotherapy on Male Germ Cells
Launched by UNIVERSITY OF PITTSBURGH · Nov 28, 2016
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how chemotherapy affects the DNA in sperm for men undergoing cancer treatment. Researchers want to understand the short-term impact of chemotherapy on male reproductive health by collecting semen samples from participants before starting treatment and then again one week after their first round of chemotherapy.
If you're a male between the ages of 18 and 62 and scheduled to receive chemotherapy, you may be eligible to participate. It’s important that you can produce semen samples both before and after starting treatment. However, men who have had chemotherapy before or those with significant issues producing sperm may not qualify. By joining this study, you can help us learn more about the effects of chemotherapy on male fertility, which could benefit future patients.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Be scheduled to undergo treatment with chemotherapeutic agents for a medical indication
- • Be able to produce semen samples prior to chemotherapy and one week after first round of chemotherapy
- Exclusion Criteria:
- • Men who have previously been treated with chemotherapeutic agents.
- • Men with significant oligospermia or azospermia.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Kyle Orwig, PhD
Principal Investigator
University of Pittsburgh/University of Pittsburgh Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials